Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06431594




Registration number
NCT06431594
Ethics application status
Date submitted
21/05/2024
Date registered
28/05/2024
Date last updated
28/05/2024

Titles & IDs
Public title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors
Scientific title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects With Advanced Solid Tumors
Secondary ID [1] 0 0
2024-513860-25
Secondary ID [2] 0 0
222730
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Solid Tumors 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GSK5733584

Experimental: Part 1: Dose Escalation -

Experimental: Part 2: Dose Expansion -


Treatment: Drugs: GSK5733584
GSK5733584 will be administered
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part 1: Number of participants with dose limiting toxicity (DLT)
Timepoint [1] 0 0
Up to 21 days
Primary outcome [2] 0 0
Part 2: Objective Response Rate (ORR)
Timepoint [2] 0 0
Up to approximately 28 months
Secondary outcome [1] 0 0
Part 1 and 2: Maximum observed concentration (Cmax) of GSK5733584
Timepoint [1] 0 0
Up to approximately 31 months
Secondary outcome [2] 0 0
Part 1 and 2: Time to reach Cmax (Tmax) of GSK5733584
Timepoint [2] 0 0
Up to approximately 31 months
Secondary outcome [3] 0 0
Part 1 and 2: Area under the concentration-time curve (AUC) of GSK5733584
Timepoint [3] 0 0
Up to approximately 31 months
Secondary outcome [4] 0 0
Part 1: Objective Response Rate (ORR)
Timepoint [4] 0 0
Up to approximately 31 months
Secondary outcome [5] 0 0
Part 1 and 2: Disease control rate (DCR)
Timepoint [5] 0 0
Up to approximately 31 months
Secondary outcome [6] 0 0
Part 1 and 2: Duration of response (DoR)
Timepoint [6] 0 0
Up to approximately 31 months
Secondary outcome [7] 0 0
Part 1 and 2: Progression-free survival (PFS)
Timepoint [7] 0 0
Up to approximately 31 months
Secondary outcome [8] 0 0
Part 1 and 2:Number of participants with treatment-emergent Anti-drug antibodies (ADA)
Timepoint [8] 0 0
Up to approximately 31 months
Secondary outcome [9] 0 0
Part 1 and 2: Titers of ADA to GSK5733584
Timepoint [9] 0 0
Up to approximately 31 months
Secondary outcome [10] 0 0
Part 1 and 2: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [10] 0 0
Up to approximately 31 months
Secondary outcome [11] 0 0
Part 1 and 2: Number of participants with clinically significant changes in physical examination
Timepoint [11] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [12] 0 0
Part 1 and 2: Change from baseline in body temperature (degree Celsius)
Timepoint [12] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [13] 0 0
Part 1 and 2: Change from baseline in respiratory rate (breaths per minute)
Timepoint [13] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [14] 0 0
Part 1 and 2: Change from baseline in pulse rate (beats per minute)
Timepoint [14] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [15] 0 0
Part 1 and 2: Change from baseline in blood pressure [millimetres of mercury (mmHg)]
Timepoint [15] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [16] 0 0
Part 1 and 2: Change from baseline in weight [kilogram (kg)]
Timepoint [16] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [17] 0 0
Part 1 and 2: Change from baseline in white blood cell count (cells per microliter)
Timepoint [17] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [18] 0 0
Part 1 and 2: Change from baseline in hemoglobin (grams per deciliter)
Timepoint [18] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [19] 0 0
Part 1 and 2: Change from Baseline in Platelet count (cells per microliter)
Timepoint [19] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [20] 0 0
Part 1 and 2: Change from Baseline in Red Blood Cell Count (RBC) (million cells per microliter)
Timepoint [20] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [21] 0 0
Part 1 and 2: Change from Baseline in haematocrit (Proportion of red blood cells in blood)
Timepoint [21] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [22] 0 0
Part 1 and 2: Change from Baseline in Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per litre)
Timepoint [22] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [23] 0 0
Part 1 and 2: Change from Baseline in Glucose (fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Chloride, Magnesium Direct Bilirubin and Total Bilirubin (milligrams per decilitre)
Timepoint [23] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [24] 0 0
Part 1 and 2: Change from Baseline in AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per litre)
Timepoint [24] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [25] 0 0
Part 1 and 2: Change from baseline in Total Protein and Albumin (Grams per deciliter)
Timepoint [25] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [26] 0 0
Part 1 and 2: Change from baseline in Amylase and Lipase (Units per liter)
Timepoint [26] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [27] 0 0
Part 1 and 2: Change from baseline in Creatinine clearance (milliliter per minute)
Timepoint [27] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [28] 0 0
Part 1 and 2: Change from baseline in Activated Partial Thromboplastin Time (aPTT), Prothrombin Time (PT) and Thrombin time (seconds)
Timepoint [28] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [29] 0 0
Part 1 and 2: Change from baseline in fibrinogen (milligrams per deciliter)
Timepoint [29] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [30] 0 0
Part 1 and 2: Change from baseline in liver panel parameter: International Normalized Ratio (INR)
Timepoint [30] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [31] 0 0
Part 1 and 2: Change from baseline in routine urine tests: Leukocyte esterase
Timepoint [31] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [32] 0 0
Part 1 and 2: Change from baseline in routine urine tests: Occult blood (10^9 Cells Per Liter)
Timepoint [32] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [33] 0 0
Part 1 and 2: Change from baseline in routine urine tests: potential of hydrogen (pH) value
Timepoint [33] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [34] 0 0
Part 1 and 2: Change from baseline in routine urine tests: Protein and bilirubin (Grams Per Liter)
Timepoint [34] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [35] 0 0
Part 1 and 2: Change From Baseline in routine urine tests: Specific Gravity (Ratio)
Timepoint [35] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [36] 0 0
Part 1 and 2: Change from baseline in CA-125 tumor marker [units per milliliter (U/mL)]
Timepoint [36] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [37] 0 0
Part 1 and 2: Change from baseline in Electrocardiogram (ECG) readings [milliseconds (msec)]
Timepoint [37] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [38] 0 0
Part 1 and 2: Change from baseline in Left ventricular ejection fraction (LVEF) [Percentage]
Timepoint [38] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [39] 0 0
Part 1 and 2: Change from baseline in Eastern Cooperative Oncology Group Performance Scale (ECOG PS) score
Timepoint [39] 0 0
Baseline (Day -1) and up to approximately 31 months
Secondary outcome [40] 0 0
Part 2: Overall Survival (OS)
Timepoint [40] 0 0
Up to approximately 31 months

Eligibility
Key inclusion criteria
- Males or females aged 18 years or older (=18 years).

- Participants with pathologically confirmed advanced solid tumor (who have failed or
are intolerant to standard of care).

- Participants have at least one target lesion as assessed per the RECIST 1.1

- Tumor tissue from a newly obtained biopsy or archival tumor tissue is required for
retrospective detection of B7 homolog 4 (B7-H4) expression by Immunohistochemistry
(IHC) in central laboratory and other biomarker analysis. Tissue from a newly obtained
biopsy is preferred. If a newly obtained biopsy is not feasible, archival tumor tissue
within 2 years prior to the first dose of study drug is acceptable.

- Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2 and no
deterioration within 2 weeks before the first dose.

- Have a life expectancy of at least 12 weeks.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Have received any of B7-H4-targeted therapies.

- Have received any of cytotoxic chemotherapy drugs, anti-tumor traditional Chinese
medicines or other anti-tumor drugs within 28 days prior to the first dose of study
drug; or need to continue these drugs during the study.

- Have received locoregional radiation therapy within 2 weeks prior to the first dose of
study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy
within 4 weeks prior to the first dose of study treatment.

- Presence of pleural/abdominal effusion/ascites requiring clinical intervention;
presence of pericardial effusion

- Major surgery within 4 weeks prior to the first dose of study treatment.

- Evidence of brain metastasis unless asymptomatic.

- Has inadequate bone marrow reserve or hepatic/renal functions.

- Mean Fridericia-corrected QT interval (QTcF) > 470 millisecond (msec) on resting ECG.

- Evidence of current clinically significant arrhythmias or ECG abnormalities

- Risk factors of prolonged QTc or arrhythmia events,

- Left ventricular ejection fraction (LVEF) < 50%.

- Have severe, uncontrolled or active cardiovascular disorders, serious or poorly
controlled hypertension, clinically significant bleeding symptoms or serious
arteriovenous thromboembolic events

- Any evidence of current Interstitial lung disease (ILD) or pneumonitis or a prior
history of ILD or pneumonitis requiring high-dose systemic glucocorticoids.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
29/05/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
21/01/2027
Actual
Sample size
Target
240
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
GSK Investigational Site - Sydney
Recruitment postcode(s) [1] 0 0
2109 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Massachusetts
Country [3] 0 0
United States of America
State/province [3] 0 0
Michigan
Country [4] 0 0
United States of America
State/province [4] 0 0
Texas
Country [5] 0 0
United States of America
State/province [5] 0 0
Utah
Country [6] 0 0
Canada
State/province [6] 0 0
Ontario

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The goal of this study is to assess the safety and tolerability of GSK5733584. The study will
also see how the levels of GSK5733584 change over time at different dose amount.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06431594
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
US GSK Clinical Trials Call Center
Address 0 0
Country 0 0
Phone 0 0
877-379-3718
Fax 0 0
Email 0 0
GSKClinicalSupportHD@gsk.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06431594